Difference between revisions of "TFE3"
Jump to navigation
Jump to search
(create) |
|||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{ Infobox immunostain | |||
| Name = {{PAGENAME}} | |||
| Image = | |||
| Width = | |||
| Caption = | |||
| Abbrev = | |||
| Synonyms = | |||
| Similar = | |||
| Clones = | |||
| Use = screen to detect TFE3 rearrangements | |||
| Subspecial = [[urologic pathology]], [[soft tissue pathology]] | |||
| Pattern = nuclear stain | |||
| Positive = [[Xp11.2 translocation carcinoma]], [[alveolar soft part sarcoma]] | |||
| Negative = normal tissues | |||
| Other = | |||
}} | |||
'''TFE3''' is an [[immunostain]] used in [[uropathology]] and [[soft tissue pathology]]. | '''TFE3''' is an [[immunostain]] used in [[uropathology]] and [[soft tissue pathology]]. | ||
The reliability of the immunostain for detecting TFE3 rearrangments has been questioned by at least one study.<ref name=pmid30851332>{{cite journal |vauthors=Sharain RF, Gown AM, Greipp PT, Folpe AL |title=Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: a comparative, 2-laboratory study |journal=Hum Pathol |volume=87 |issue= |pages=65–74 |date=May 2019 |pmid=30851332 |doi=10.1016/j.humpath.2019.02.008 |url=}}</ref> | |||
==Negative== | ==Negative== | ||
*Normal tissue.<ref>URL: [http://www.ihcworld.com/_newsletter/2003/focus_jul_2003.pdf http://www.ihcworld.com/_newsletter/2003/focus_jul_2003.pdf]. Accessed on: September 11, 2017.</ref> | *Normal tissue.<ref>URL: [http://www.ihcworld.com/_newsletter/2003/focus_jul_2003.pdf http://www.ihcworld.com/_newsletter/2003/focus_jul_2003.pdf]. Accessed on: September 11, 2017.</ref> | ||
**Staining in normal tissue described as "extremely rare" - negative in adrenal gland, breast, colon, gallbaldder, lymph node, liver, prostate and skin.<ref name=pmid12766578>{{Cite journal | last1 = Argani | first1 = P. | last2 = Lal | first2 = P. | last3 = Hutchinson | first3 = B. | last4 = Lui | first4 = MY. | last5 = Reuter | first5 = VE. | last6 = Ladanyi | first6 = M. | title = Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. | journal = Am J Surg Pathol | volume = 27 | issue = 6 | pages = 750-61 | month = Jun | year = 2003 | doi = | PMID = 12766578 }}</ref> | |||
==Positive== | ==Positive== | ||
*[[Xp11.2 translocation carcinoma]]. | *[[Xp11.2 translocation carcinoma]]. | ||
*[[Alveolar soft part sarcoma]]. | *[[Alveolar soft part sarcoma]]. | ||
* YAP-TFE3 translocated [[epithelioid hemangioendothelioma]] | |||
*[[Epithelioid angiomyolipoma]]. | |||
*[[Granular cell tumour]].<ref>{{cite journal |authors=Chamberlain BK, McClain CM, Gonzalez RS, Coffin CM, Cates JM |title=Alveolar soft part sarcoma and granular cell tumor: an immunohistochemical comparison study |journal=Hum. Pathol. |volume=45 |issue=5 |pages=1039–44 |date=May 2014 |pmid=24746209 |doi=10.1016/j.humpath.2013.12.021 |url=}}</ref> | |||
==See also== | ==See also== | ||
Latest revision as of 03:49, 16 October 2023
| TFE3 | |
|---|---|
| Immunostain in short | |
| Use | screen to detect TFE3 rearrangements |
| Subspeciality | urologic pathology, soft tissue pathology |
| Normal staining pattern | nuclear stain |
| Positive | Xp11.2 translocation carcinoma, alveolar soft part sarcoma |
| Negative | normal tissues |
TFE3 is an immunostain used in uropathology and soft tissue pathology.
The reliability of the immunostain for detecting TFE3 rearrangments has been questioned by at least one study.[1]
Negative
- Normal tissue.[2]
- Staining in normal tissue described as "extremely rare" - negative in adrenal gland, breast, colon, gallbaldder, lymph node, liver, prostate and skin.[3]
Positive
- Xp11.2 translocation carcinoma.
- Alveolar soft part sarcoma.
- YAP-TFE3 translocated epithelioid hemangioendothelioma
- Epithelioid angiomyolipoma.
- Granular cell tumour.[4]
See also
References
- ↑ "Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: a comparative, 2-laboratory study". Hum Pathol 87: 65–74. May 2019. doi:10.1016/j.humpath.2019.02.008. PMID 30851332.
- ↑ URL: http://www.ihcworld.com/_newsletter/2003/focus_jul_2003.pdf. Accessed on: September 11, 2017.
- ↑ Argani, P.; Lal, P.; Hutchinson, B.; Lui, MY.; Reuter, VE.; Ladanyi, M. (Jun 2003). "Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay.". Am J Surg Pathol 27 (6): 750-61. PMID 12766578.
- ↑ Chamberlain BK, McClain CM, Gonzalez RS, Coffin CM, Cates JM (May 2014). "Alveolar soft part sarcoma and granular cell tumor: an immunohistochemical comparison study". Hum. Pathol. 45 (5): 1039–44. doi:10.1016/j.humpath.2013.12.021. PMID 24746209.